Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 22 Sep 23 424B3 Prospectus supplement
- 21 Sep 23 424B3 Prospectus supplement
- 15 Aug 23 EFFECT Notice of effectiveness
- 14 Aug 23 424B3 Prospectus supplement
- 10 Aug 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 4 Aug 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 17 Jul 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 26 Jun 23 S-4/A Registration of securities issued in business combination transactions (amended)
-
15 May 23 S-4 Registration of securities issued in business combination transactions
NKGN similar filings
- 4 Aug 23 Registration of securities issued in business combination transactions (amended)
- 17 Jul 23 Registration of securities issued in business combination transactions (amended)
- 26 Jun 23 Registration of securities issued in business combination transactions (amended)
- 15 May 23 Registration of securities issued in business combination transactions
Filing view
External links
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated May 15, 2023, with respect to the financial statements of NKGen Biotech, Inc. included in the preliminary proxy statement/prospectus of Graf Acquisition Corp. IV. that is made a part of the Registration Statement (Form S-4) and Prospectus of Graf Acquisition Corp. IV. for the registration of shares of its common stock.
/s/ Ernst & Young LLP
Irvine, California
May 15, 2023